This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Travis WD , Brambilla E , Nicholson AG , Yatabe Y , Austin JHM , Beasley MB , Chirieac LR , Dacic S , Duhig E , Flieder DB , Geisinger K , Hirsch FR , Ishikawa Y , Kerr KM , Noguchi M , Pelosi G , Powell CA , Tsao MS , Wistuba I , WHOPanel
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
J Thorac Oncol. 2015 Sep;10(9) :1243-1260
PMID: 26291008 URL: https://www.ncbi.nlm.nih.gov/pubmed/26291008
AbstractThe 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification. The most significant changes in this edition involve (1) use of immunohistochemistry throughout the classification, (2) a new emphasis on genetic studies, in particular, integration of molecular testing to help personalize treatment strategies for advanced lung cancer patients, (3) a new classification for small biopsies and cytology similar to that proposed in the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (4) a completely different approach to lung adenocarcinoma as proposed by the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, (5) restricting the diagnosis of large cell carcinoma only to resected tumors that lack any clear morphologic or immunohistochemical differentiation with reclassification of the remaining former large cell carcinoma subtypes into different categories, (6) reclassifying squamous cell carcinomas into keratinizing, nonkeratinizing, and basaloid subtypes with the nonkeratinizing tumors requiring immunohistochemistry proof of squamous differentiation, (7) grouping of neuroendocrine tumors together in one category, (8) adding NUT carcinoma, (9) changing the term sclerosing hemangioma to sclerosing pneumocytoma, (10) changing the name hamartoma to "pulmonary hamartoma," (11) creating a group of PEComatous tumors that include (a) lymphangioleiomyomatosis, (b) PEComa, benign (with clear cell tumor as a variant) and
NotesTravis, William D Brambilla, Elisabeth Nicholson, Andrew G Yatabe, Yasushi Austin, John H M Beasley, Mary Beth Chirieac, Lucian R Dacic, Sanja Duhig, Edwina Flieder, Douglas B Geisinger, Kim Hirsch, Fred R Ishikawa, Yuichi Kerr, Keith M Noguchi, Masayuki Pelosi, Giuseppe Powell, Charles A Tsao, Ming Sound Wistuba, Ignacio eng Editorial Historical Article J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630.